Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT07022483
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
710 Enrollment(s)
40 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer
ACTIVE_NOT_RECRUITING
NCT06771622
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
500 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Solid Cancer
RECRUITING
NCT06650501
Dabigatran vs. Apixaban, Edoxaban, or Rivaroxaban as Anti-thrombotic Therapy in Patients With S. Aureus Bacteremia
300 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Staphylococcus Aureus Endocarditis


Staphylococcus Aureus Septicemia


Staphylococcus Aureus Bacteremia


Staphylococcus Aureus Bloodstream Infection


S. Aureus Bacteremia


S. Aureus Bloodstream Infection
ACTIVE_NOT_RECRUITING
NCT03742102
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
243 Enrollment(s)
32 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Triple Negative Breast Neoplasms
NOT_YET_RECRUITING
NCT07368543
Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
216 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer
RECRUITING
NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
250 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Fibrosis Syndrome


Lymphedema


Head &Amp; Neck Cancer


Fibrosis
RECRUITING
NCT04482309
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
468 Enrollment(s)
123 Study location(s)
INTERVENTIONAL (PHASE2)
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer


Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
ACTIVE_NOT_RECRUITING
NCT05633979
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
17 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer